Patent · US Active

Forms of rifaximin and uses thereof

US9133217B2 · kind B2 · utility

6Cited by

7References

16Claims

0Family size

Assignee

Salix Pharmaceuticals, Inc. · US

Inventors

Stephan D. Parent · West Lafayette, US
Lisa Lynn McQueen · West Lafayette, US
Patricia Andres · West Lafayette, US
Paul Schields · West Lafayette, US
Yiduo Wu · New Brunswick, US
Fei Ding · Overland Park, US
Jared P. Smit · Lafayette, US

Key dates

Filing date	May 27, 2014
Grant date	Sep 15, 2015
Priority date	—
Expiry date	May 27, 2034

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.